Janux Therapeutics (JANX) awards RSUs and stock options to director
Rhea-AI Filing Summary
Janux Therapeutics director Ronald W. Barrett received new equity awards. He was granted 5,500 restricted stock units, each representing one share of common stock, increasing his direct common stock holdings to 11,750 shares. He also received a stock option for 15,500 shares at an exercise price of $13.66 per share, expiring on June 10, 2036.
The RSUs vest on the earlier of June 11, 2027 or the next annual stockholder meeting, subject to his continuous service. The option vests in equal monthly installments over the 12 months following June 11, 2026, and will in any case be fully vested by the next annual stockholder meeting, also contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Barrett Ronald W
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 15,500 | $0.00 | -- |
| Grant/Award | Common Stock | 5,500 | $0.00 | -- |
Holdings After Transaction:
Stock Option (right to buy) — 15,500 shares (Direct);
Common Stock — 11,750 shares (Direct)
Footnotes (1)
- Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest on the earlier of (i) June 11, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders, in each case, subject to the Reporting Person's continuous service on such date. The shares subject to the option will vest in equal monthly installments over the 12 months following June 11, 2026, provided that the shares subject to the option will in any case be fully vested on the date of the next annual meeting of the Issuer's stockholders, subject to the Reporting Person's continuous service on each such date.
Key Figures
RSU grant: 5,500 shares
Option grant size: 15,500 shares
Option exercise price: $13.66 per share
+2 more
5 metrics
RSU grant
5,500 shares
Restricted stock units granted on June 11, 2026
Option grant size
15,500 shares
Stock option (right to buy) granted on June 11, 2026
Option exercise price
$13.66 per share
Exercise price for 15,500-share stock option
Option expiration
June 10, 2036
Expiration date of stock option grant
Common shares after grant
11,750 shares
Total common stock held directly after RSU award
Key Terms
restricted stock units ("RSUs"), Stock Option (right to buy), continuous service, annual meeting of the Issuer's stockholders
4 terms
restricted stock units ("RSUs") financial
"Represents the grant of restricted stock units ("RSUs"), each of which represents a contingent right..."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
Stock Option (right to buy) financial
"Stock Option (right to buy) with an exercise price of $13.6600 per share..."
continuous service financial
"subject to the Reporting Person's continuous service on such date."
annual meeting of the Issuer's stockholders financial
"the date of the next annual meeting of the Issuer's stockholders..."
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Janux Therapeutics (JANX) report for Ronald W. Barrett?
Janux Therapeutics reported that director Ronald W. Barrett received 5,500 restricted stock units and a stock option for 15,500 shares. Both awards are compensation grants, not open-market purchases or sales, and are subject to future vesting based on his continued service.
What are the vesting terms for the 5,500 RSUs granted by Janux Therapeutics (JANX)?
The 5,500 RSUs vest on the earlier of June 11, 2027 or the date of Janux’s next annual stockholder meeting. Vesting is conditioned on Ronald W. Barrett’s continuous service with the company through the applicable vesting date.
What are the key terms of Ronald W. Barrett’s stock option grant at Janux Therapeutics (JANX)?
The stock option covers 15,500 shares of common stock at a $13.66 exercise price and expires June 10, 2036. It vests in equal monthly installments over 12 months after June 11, 2026, or is fully vested at the next annual meeting, subject to continued service.
Does the Janux Therapeutics (JANX) Form 4 show open-market buying or selling by Ronald W. Barrett?
The Form 4 shows compensation-related equity grants, not open-market buying or selling. Ronald W. Barrett acquired RSUs and an option at no cash cost per share, with future vesting conditions tied to his continued service as a director.